Key Points
- Electromed CFO Bradley Nagel sold 11,801 shares on June 4 at an average price of $36.35, totaling about $428,966.35. After the sale, he still owned 19,638 shares valued at roughly $713,841.30.
- The transaction reduced Nagel’s stake in the company by 37.54%, and it was disclosed in an SEC filing.
- Electromed stock has been strong recently, opening at $37.08 with a market cap of $307.02 million. Analysts remain bullish overall, with a consensus Buy rating and an average price target of $37.50.
Electromed, Inc. (NYSE:ELMD - Get Free Report) CFO Bradley Nagel sold 11,801 shares of Electromed stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $36.35, for a total transaction of $428,966.35. Following the transaction, the chief financial officer directly owned 19,638 shares of the company's stock, valued at approximately $713,841.30. This trade represents a 37.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Electromed Price Performance
Shares of NYSE ELMD opened at $37.08 on Tuesday. Electromed, Inc. has a 1 year low of $17.73 and a 1 year high of $40.00. The stock has a market cap of $307.02 million, a P/E ratio of 49.44 and a beta of 0.53. The firm has a 50-day moving average of $29.79 and a 200 day moving average of $27.87.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its stake in shares of Electromed by 717.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 106,005 shares of the company's stock worth $3,087,000 after acquiring an additional 93,030 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Electromed by 10.3% in the third quarter. JPMorgan Chase & Co. now owns 70,983 shares of the company's stock worth $1,743,000 after acquiring an additional 6,612 shares during the period. Aristides Capital LLC grew its stake in shares of Electromed by 13.4% in the third quarter. Aristides Capital LLC now owns 29,570 shares of the company's stock worth $726,000 after acquiring an additional 3,494 shares during the period. Teton Advisors LLC bought a new stake in shares of Electromed in the third quarter worth approximately $491,000. Finally, Navellier & Associates Inc. grew its stake in shares of Electromed by 29.6% in the third quarter. Navellier & Associates Inc. now owns 59,357 shares of the company's stock worth $1,457,000 after acquiring an additional 13,543 shares during the period. 40.82% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of brokerages recently issued reports on ELMD. B. Riley Financial lifted their price target on shares of Electromed from $38.00 to $40.00 and gave the company a "buy" rating in a research report on Wednesday, May 13th. Zacks Research raised shares of Electromed from a "hold" rating to a "strong-buy" rating in a report on Wednesday, May 13th. Finally, Roth Mkm reaffirmed a "buy" rating and issued a $38.00 target price on shares of Electromed in a report on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. Based on data from MarketBeat, Electromed has a consensus rating of "Buy" and a consensus price target of $37.50.
Get Our Latest Analysis on Electromed
Electromed Company Profile
(
Get Free Report)
Electromed Inc (NYSE: ELMD) develops and manufactures sleep therapy products designed to support individuals with breathing disorders such as obstructive sleep apnea. The company's core business activities include the design, production and distribution of continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP) accessories. Electromed's focus on supplying both disposable and reusable components allows durable medical equipment providers to offer comprehensive therapy solutions to patients.
The company's product portfolio encompasses masks, mask cushions, headgear, tubing, filters and humidification components.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
